128 related articles for article (PubMed ID: 16434058)
1. Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer.
Barth VN; Chernet E; Martin LJ; Need AB; Rash KS; Morin M; Phebus LA
Life Sci; 2006 May; 78(26):3007-12. PubMed ID: 16434058
[TBL] [Abstract][Full Text] [Related]
2. Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples.
Chernet E; Martin LJ; Li D; Need AB; Barth VN; Rash KS; Phebus LA
Life Sci; 2005 Dec; 78(4):340-6. PubMed ID: 16139310
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D2 receptor radiotracers [(11)C](+)-PHNO and [(3)H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo.
McCormick PN; Kapur S; Seeman P; Wilson AA
Nucl Med Biol; 2008 Jan; 35(1):11-7. PubMed ID: 18158938
[TBL] [Abstract][Full Text] [Related]
4. SIC, an intracerebral beta(+)-range-sensitive probe for radiopharmacology investigations in small laboratory animals: binding studies with (11)C-raclopride.
Zimmer L; Hassoun W; Pain F; Bonnefoi F; Lanièce P; Mastrippolito R; Pinot L; Pujol JF; Leviel V
J Nucl Med; 2002 Feb; 43(2):227-33. PubMed ID: 11850489
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action.
Kapur S; Seeman P
J Psychiatry Neurosci; 2000 Mar; 25(2):161-6. PubMed ID: 10740989
[TBL] [Abstract][Full Text] [Related]
6. Amphetamine pretreatment induces a change in both D2-Receptor density and apparent affinity: a [11C]raclopride positron emission tomography study in cats.
Ginovart N; Wilson AA; Houle S; Kapur S
Biol Psychiatry; 2004 Jun; 55(12):1188-94. PubMed ID: 15184038
[TBL] [Abstract][Full Text] [Related]
7. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats.
Turrone P; Remington G; Kapur S; Nobrega JN
Psychopharmacology (Berl); 2003 Jan; 165(2):166-71. PubMed ID: 12417967
[TBL] [Abstract][Full Text] [Related]
8. Receptor occupancy and brain free fraction.
Watson J; Wright S; Lucas A; Clarke KL; Viggers J; Cheetham S; Jeffrey P; Porter R; Read KD
Drug Metab Dispos; 2009 Apr; 37(4):753-60. PubMed ID: 19158315
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors.
Seeman P; Tallerico T
Mol Psychiatry; 1998 Mar; 3(2):123-34. PubMed ID: 9577836
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous in-vivo receptor occupancy assays for serotonin 1A, 2A, and dopamine 2 receptors with the use of non-radiolabelled tracers: Proposed method in screening antipsychotics.
Thentu JB; Nirogi R; Bhyrapuneni G; Ajjala DR; Aleti RR; Palacharla RC
J Pharmacol Toxicol Methods; 2017; 85():22-28. PubMed ID: 28063918
[TBL] [Abstract][Full Text] [Related]
11. Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers.
Lim KS; Kwon JS; Jang IJ; Jeong JM; Lee JS; Kim HW; Kang WJ; Kim JR; Cho JY; Kim E; Yoo SY; Shin SG; Yu KS
Clin Pharmacol Ther; 2007 Feb; 81(2):252-8. PubMed ID: 17259948
[TBL] [Abstract][Full Text] [Related]
12. Development of a population pharmacokinetic model to predict brain distribution and dopamine D2 receptor occupancy of raclopride in non-anesthetized rat.
Wong YC; Ilkova T; van Wijk RC; Hartman R; de Lange ECM
Eur J Pharm Sci; 2018 Jan; 111():514-525. PubMed ID: 29106979
[TBL] [Abstract][Full Text] [Related]
13. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
Olsen CK; Brennum LT; Kreilgaard M
Eur J Pharmacol; 2008 Apr; 584(2-3):318-27. PubMed ID: 18325493
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride.
Mukherjee J; Christian BT; Narayanan TK; Shi B; Mantil J
Neuropsychopharmacology; 2001 Oct; 25(4):476-88. PubMed ID: 11557161
[TBL] [Abstract][Full Text] [Related]
15. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.
Assié MB; Dominguez H; Consul-Denjean N; Newman-Tancredi A
Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep; 373(6):441-50. PubMed ID: 16947046
[TBL] [Abstract][Full Text] [Related]
16. Raclopride and chlorpromazine, but not clozapine, increase muscle rigidity in the rat: relationship with D2 dopamine receptor occupancy.
Hemsley KM; Crocker AD
Neuropsychopharmacology; 1999 Jul; 21(1):101-9. PubMed ID: 10379524
[TBL] [Abstract][Full Text] [Related]
17. Dopamine displaces [3H]domperidone from high-affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: Implications for human positron emission tomography.
Seeman P; Tallerico T; Ko F
Synapse; 2003 Sep; 49(4):209-15. PubMed ID: 12827639
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo [11C]-(+)-PHNO binding is unchanged in animal models displaying increased high-affinity states of the D2 receptor in vitro.
McCormick PN; Kapur S; Reckless G; Wilson AA
Synapse; 2009 Nov; 63(11):998-1009. PubMed ID: 19598174
[TBL] [Abstract][Full Text] [Related]
19. Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat.
Naiker DV; Catts SV; Catts VS; Bedi KS; Bryan-Lluka LJ
Eur J Pharmacol; 2006 Jul; 540(1-3):87-90. PubMed ID: 16730699
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy.
Kapur S; VanderSpek SC; Brownlee BA; Nobrega JN
J Pharmacol Exp Ther; 2003 May; 305(2):625-31. PubMed ID: 12606608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
